The implications of antigenic diversity for vaccine development

Immunology Letters

Volumn 66, Issue 1-3, 1999, Pages 159-164

  Zolla Pazner, Susan ^a,b   Gomy, Miroslaw K ^b   Nyambi, Phillipe N ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibodies; Epitopes; HIV 1; Neutralization; Vaccines

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGENICITY; CONFERENCE PAPER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENIC VARIATION; CROSS REACTIONS; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS;

EID: 0033019853     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(98)00176-X     Document Type: Conference Paper

References (49)

1. Janssens W., Heyndrickx L., Fransen K. et al. AIDS Res. Hum. Retrovir. 10:1994;877-879.
2. Janssens W., Nkengasong J.N., Heyndricbx L. et al. AIDS. 8:1994;1012-1013.
3. Kostrikis L.G., Michalopoulou Z., Ho D.D. J. Virol. 69:1995;6122-6130.
4. Nkengasong J.N., Janssens W., Heyndrickx L. et al. AIDS. 8:1994;1405-1412.
5. Myers G., Maclnnes K., Korber B. AIDS Res. Hum. Retrovir. 8:1992;373-386.
6. Lonwagie J., McCutchan F.E., Peeters M. et al. AIDS. 7:1993;769-780.
7. Myers G., Korber B., Foley B. et al. Theoretical Biology and Biophysics, Los Alamos National Laboratories. 1996;Los Alamos, New Mexico.
8. Robertson D.L., Sharp P.M., McCutchan F., Hahn B.H. Nature. 374:1995;124-125.
9. Gorny M.K., Xu J., Karwowska S., Buchbinder A., Zolla-Pazner S. J. Immunol. 150:1993;635-643.
10. Gorny M.K., VanCoth T.C., Hioe C. et al. J. Immunol. 159:1997;5114-5122.
11. Gorny M.K., Mascola J.R., Israel Z.R. et al. AIDS Res. Hum. Retrovir. 14:1998;213-221.
12. Gorny M.K., Xu J.-Y., Gianakakos V. et al. Proc. Natl. Acad. Sci. USA. 88:1991;3238-3242.
13. Moore J.P., McCutchan F.E., Poon S. et al. J. Virol. 68:1994;8350-8364.
14. N.L. Haigwood, C.B. Barker, K.W. Higgens et al., Vaccines 90: Modern approaches to new vaccines including prevention of AIDS , in: F. Brown, R M. Chanock, H. Ginsberg, R.A. Luner (Eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1991, pp. 313-320.
15. Trkola A., Pomales A.B., Yuan H. et al. J. Virol. 69:1995;6609-6617.
16. McKeating J.A., Shotton C., Cordell J. et al. J. Virol. 67:1993;4932-4944.
17. Israel Z.R., Gomy M.K., Palmer C., McKeating J.A., Zolla-Pazner S. AIDS. 11:1997;128-130.
18. Kayman S.C., Revesz Z.W.K., Chen J., Kopelman R., Pinter A. J. Virol. 68:1994;400-410.
19. Gorny M.K., Moore J.P., Conley A.J. et al. J. Virol. 68:1994;8312-8320.
20. Xu J.-Y., Gorny M.K., Palker T., Karwowska S., Zolla-Pazner S. J. Virol. 65:1991;4832-4838.
21. Burton D., Pyati R., Koduri J. et al. Science. 266:1994;1024-1027.
22. Kessler J.A., Mckenna P.M., Emini E.A. et al. AIDS Res. Hum. Retrovir. 13:1997;575-582.
23. Moore J.P., Cao Y., Qing L. et al. J. Virol. 69:1995;101-109.
24. Moore J.P., Sattentau Q., Wyatt R., Sodroski J. J. Virol. 68:1994;469-484.
25. Broder C.C., Earl P.L., Long D., Abedon S.T., Moss B., Dorns R.W. Proc. Natl. Acad. Sci. (USA). 91:1994;11699-11703.
26. Sattentau Q.J., Moore J.P. J. Exp. Med. 182:1995;185-196.
27. Stamatatos L., Cheng-Mayer C. J. Virol. 69:1995;6191-6198.
28. Sullivan N., Sun Y., Li J., Hofinann W., Sodroski J. J. Virol. 69:1995;4413-4422.
29. Nyambi P.N., Nkengasong J., Peeters M. et al. J. Infect. Dis. 172:1995;1228-1237.
30. Moore J.P., Cao Y., Leu J., Qin L., Korber B., Ho D.D. J. Virol. 70:1996;427-444.
31. Nyambi P.N., Gorny M.K., Bastiani L., van der Groen G., Williams C., Zolla-Pazner S. J. Virol. 72:1998;9384-9391.
32. Weber J., Fenyo E.M., Beddows S., Kaleebu P., Bjomdal A. The Who Network for HIV Isolation and Characterization. J. Virol. 70:1996;7827-7832.
33. Kostrikis L.G., Cao Y., Ngai H., Moore J.P., Ho D.D. J. Virol. 70:1996;445-458.
34. Nyambi P.N., Nkengasong J., Lewi P. J. Virol. 70:1996;6235-6243.
35. Barin F., Lahbabi Y., Buzelay L. et al. AIDS Res. Hum. Retrovir. 12:1996;1279-1289.
36. Lewi P.J. Drug Res. 26:1976;1295-1300.
37. Lewi P.J. Research Studies Press. 1982;Wiley, Chichester, England.
38. Andries K., Dewindt B., Snoek J. et al. J. Virol. 64:1990;1117-1123.
39. Horsnell C., Gama R.E., Hughes P.J., Stanway G. J. Gen. Virol. 76:1995;2549-2555.
40. Mori J., Clewley J.P. J. Med. Virol. 44:1994;323-329.
41. Vogel T., Kurth R., Norley S. J. Immunol. 153:1994;1895-1904.
42. Nyambi P.N., Willems B., Janssens W. et al. AIDS Res. Hum. Retrovir. 13:1996;7-17.
43. P.N. Nyambi, L. Heyndrickx, W. Janssens et al., Conference on Advancesin AIDS Vaccine Development, Program Book of the 9th Annual Meeting of the National CooperativeVaccine Development Groups for AIDS, Bethesda, MD, May 4-7, Poster 60, 1997, p. 165.
44. Zolla-Pazner S., O'Leary J., Burda S. et al. J. Virol. 69:1995;3807-3815.
45. Vijh-Warrier S., Pinter A., Honnen W.J., Tilley S.A. J. Virol. 70:1996;4466-4473.
46. Moore J.P., Trkola A., Korber B. et al. J. Virol. 69:1995;122-130.
47. Kessler II J.A., McKenna P.M., Emini E.A. et al. AIDS Res. Hum. Retrovir. 13:1997;575-582.
48. Conley A.J., Kessler J.A., Boots L.J. et al. Proc. Natl. Acad. Sci. USA. 91:1994;3348-3352.
49. Posner M.R., Hideshima T., Cannon T., Mukherjee M., Mayer K.H., Bym R. J. Immunol. 146:1991;4325-4332.